Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Market share of top 20 companies for orphan drugs worldwide 2018 and 2024

Top 20 pharmaceutical companies worldwide by orphan drug revenue market share in 2024 compared to 2018*

by Matej Mikulic, last edited Aug 9, 2019
Market share of top 20 companies for orphan drugs worldwide 2018 and 2024 Among companies that marketed orphan drugs in 2018, Celgene held the largest percentage of the orphan drug market at that time. It is projected that by 2024 Celgene will still hold the largest percentage of the orphan drug market but significantly less than in 2018. Celgene's orphan drug market share in 2018 was nearly 10 percent, but until 2024, the company's orphan drug market share is expected to drop to 5.6 percent. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Ophan drugs overview

Orphan drugs are pharmaceutical products designed to help treat, prevent and even diagnose extremely rare disorders and disease. A rare disease and disorder is defined as an illness that affects 1 in 2,000 people (in Europe) or one that affects less than 200,000 individuals (in the U.S.). The top orphan drug based on revenue in 2018 was Revlimid. It is a drug used to treat certain types of cancers and genetic disorders. It is projected that by 2024 the top orphan drug, by revenue, will be Imbruvica (ibrutinib).

The orphan drug market

The number of orphan drugs on the market in the U.S. had increased dramatically over the last two decades. There were over 460 drugs with an orphan distinction in the U.S. during 2017. Orphan drugs are typically significantly more expensive than non-orphan drugs. The average per patient cost of an orphan drug in the U.S. is about 4.5 times as expensive as a non-orphan drug. Despite the cost and the number of drugs available, the global orphan drug market has experienced varying degrees of growth. Data indicates that, while there will still be revenue growth in the future, the percentage of growth will begin to decline or remain stable.
Show more

Top 20 pharmaceutical companies worldwide by orphan drug revenue market share in 2024 compared to 2018*

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Orphan drugs
Orphan drugs

All Information
in one Presentation

Orphan drugs

Everything On "Orphan drugs" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Orphan drugs"
  • Market overview
  • Companies
  • Products
  • Research and development
  • Rare diseases
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: You might find this interesting as well
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.